Table 1 Effect of diflapolin on vascular permeability and myeloperoxidase (MPO) activity in zymosan-induced peritonitis.

From: Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase

 

vascular permeability

myeloperoxidase activity

absorption (610 nm)

% of vehicle control

U/mL

% of vehicle control

vehicle

0.623 ± 0.04

100

1.23 ± 0.13

100

diflapolin 10 mg/kg

0.347 ± 0.09

55.7 ± 14.4

0.65 ± 0.15

52.8 ± 12.2

MK886 1 mg/kg

n.d.

n.d.

0.72 ± 0.13

58.5 ± 10.6

MK886 3 mg/kg

0.303 ± 0.02

48.6 ± 3.2

n.d.

n.d.

  1. Male mice (n = 5 for vascular permeability, n = 7 for MPO; each group) were treated i.p. with diflapolin, MK886, or vehicle, 30 min before induction of zymosan-induced peritonitis. Analysis of vascular permeability and MPO was performed 30 min and 4 h, respectively, after zymosan injection. Data are given means ± S.E.M, (vascular permeability n = 5; myeloperoxidase activity n = 7) *p < 0.05 versus vehicle (Anova + Bonferroni). n.d., not determined.
Back to article page